Follow The Filings

MTD Mettler-Toledo

Health Care, filed as METTLER TOLEDO INTERNATIONAL (COM), Equity As of 2026 Q3 among managers we track Quote on Google Finance, opens in a new tab

Bought by 2 managers in 2026 Q2, sold by 1

  • 1 Owner
  • Max 0.3%
  • $2.5M
  • 1 add

In 2026 Q3 Torray Investment Partners added to Mettler-Toledo.

Who owns this now

Largest portfolio weights among holders, up to 0.3% (Torray Investment Partners). Not free-float ownership.

  1. Torray Investment Partners Add 0.34%

Who owns MTD

Sorted by value, long equity only, as of 2026 Q3.

History
Torray Investment Partners 0.34%, was 0.29% Add +0.7% 1,683 $2.5M History

1 current, options excluded

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by MTD's executives, directors and 10% owners in the last 12 months, from their Form 4s

All MTD insider trades
  • None no insider bought on the open market
  • $35.9M sold by 6 insiders outside a trading plan
  • None no planned (10b5-1) sales
  1. Patrick Kaltenbach CEO
    Sale
    $1.3M 942 shares at $1,425.00 17% of stake
    Traded Aug 27 Filed Aug 31
    ↗
  2. Thomas P Salice Director
    Sale
    $601K 417 shares at $1,440.41 59% of stake
    Traded Aug 5 Filed Aug 7
    ↗
  3. Thomas P Salice Director
    Sale
    $600K 415 shares at $1,444.62 59% of stake
    Traded Aug 3 Filed Aug 5
    ↗
  4. Gerry Keller Head of Process Analytics
    Sale
    $343K 240 shares at $1,427.14 48% of stake
    Traded Aug 3 Filed Aug 5
    ↗
  5. Shawn Vadala CFO
    Sale
    $3.2M 2,240 shares at $1,432.00 29% of stake
    Traded Aug 3 Filed Aug 5
    ↗
  6. Shawn Vadala CFO
    Sale
    $1.1M 800 shares at $1,410.12 13% of stake
    Traded Feb 10 Filed Feb 11
    ↗
  7. Marc De La Guerroniere Head of Eur & NA Market Orgs
    Sale
    $9M 6,055 shares at $1,488.18 97% of stake
    Traded Nov 25, 2025 Filed Nov 26, 2025
    ↗
  8. Shawn Vadala CFO
    Sale
    $3M 2,025 shares at $1,481.14 28% of stake
    Traded Nov 24–25 Filed Nov 26, 2025
    ↗
  9. Gerry Keller Head of Process Analytics
    Sale
    $335K 236 shares at $1,418.58 60% of stake
    Traded Nov 21, 2025 Filed Nov 25, 2025
    ↗
  10. Patrick Kaltenbach CEO
    Sale
    $2.9M 2,000 shares at $1,462.50 35% of stake
    Traded Nov 12, 2025 Filed Nov 13, 2025
    ↗
  11. Shawn Vadala CFO
    Sale
    $2.8M 1,895 shares at $1,455.52 26% of stake
    Traded Nov 11, 2025 Filed Nov 13, 2025
    ↗
  12. Marc De La Guerroniere Head of Eur & NA Market Orgs
    Sale
    $10M 6,880 shares at $1,450.00 97% of stake
    Traded Nov 11, 2025 Filed Nov 13, 2025
    ↗
  13. Elisha W Finney Director
    Sale
    $680K 474 shares at $1,433.57 60% of stake
    Traded Nov 10, 2025 Filed Nov 13, 2025
    ↗

Also filed in the last 12 months, not counted as buying or selling: 25 stock grants and 18 option exercises.

Congress

3 members of Congress traded MTD in the last three years: 3 buys and 3 sales. 2 members listed it in 2025 annual reports.

All Congress trades
  1. Julia Letlow R-LA-5 Sell $1K–$15K Dec 8, 2025 filed Jan 13
  2. Julia Letlow R-LA-5 Buy $1K–$15K Jul 25, 2025 filed Jan 13
  3. Julia Letlow R-LA-5 Buy $1K–$15K Dec 18, 2024 filed Jan 13
  4. Robert P. Bresnahan, Jr. R-PA-8 Buy $1K–$15K May 15, 2025 filed May 31, 2025
  5. Julie Johnson D-TX-32Joint Sell $1K–$15K Apr 1, 2025 filed May 14, 2025
  6. Robert P. Bresnahan, Jr. R-PA-8 Sell $1K–$15K Apr 8, 2025 filed Apr 28, 2025

SEC filings

Recent issuer filings from EDGAR, 17 shown.

Filed Form Detail Links
SCHEDULE 13G/A — Filing Doc
8-K 5.02,7.01,9.01 Filing Doc
SCHEDULE 13G — Filing Doc
10-Q Filing Doc
8-K 2.02,9.01 Filing Doc
8-K 5.02 Filing Doc
8-K 5.07 Filing Doc
10-Q Filing Doc
8-K 2.02,9.01 Filing Doc
SCHEDULE 13G — Filing Doc
SCHEDULE 13G/A — Filing Doc
DEF 14A Filing Doc
DEFA14A Filing Doc
SCHEDULE 13G — Filing Doc
10-K Filing Doc
8-K 2.02,9.01 Filing Doc
8-K 5.02,7.01,9.01 Filing Doc

Source: SEC EDGAR submissions, updated 13 days ago. All on EDGAR

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Revenue $3.79B $3.87B $4.03B
Gross profit $2.24B $2.33B $2.39B
Gross margin * 59.2% 60.1% 59.4%
Net income $788.78M $863.14M $869.19M
Net margin * 20.8% 22.3% 21.6%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $1.23B $1.19B $1.36B
Total non-current assets * $2.13B $2.05B $2.35B
Total assets $3.36B $3.24B $3.71B
Total current liabilities $1.18B $1.17B $1.2B
Total non-current liabilities * $2.32B $2.2B $2.54B
Total equity -$149.94M -$126.89M -$23.64M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations $965.87M $968.35M $955.77M
Cash from investing -$131.69M -$119.46M -$193.87M
Cash from financing -$859.58M -$855.98M -$755.17M
Net change in cash -$26.16M -$10.44M $7.53M

Source: SEC companyfacts (US-GAAP 10-K). A * marks a computed figure, not a single XBRL tag. Fiscal years are as the issuer labels them. Follow The Filings does not adjust or audit these figures.

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.